Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Alzheimers Dement. 2024 Aug 13. doi: 10.1002/alz.14167. Online ahead of print.
ABSTRACT
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) Clinical Core is responsible for coordination of all clinical activities at the ADNI sites, including project management, regulatory oversight, and site management and monitoring, as well as the collection of all clinical data and management of all study data. The Clinical Core is also charged with determining the clinical classifications and criteria for enrollment in evolving AD trials and enabling the ongoing characterization of the cross-sectional features and longitudinal trajectories of the ADNI cohorts with application of these findings to optimal clinical trial designs. More than 2400 individuals have been enrolled in the cohorts since the inception of ADNI, facilitating refinement of our understanding of the AD trajectory and allowing academic and industry investigators to model therapeutic trials across the disease spectrum from the presymptomatic stage through dementia. HIGHLIGHTS: Since 2004, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Clinical Core has overseen the enrollment of > 2400 participants with mild cognitive impairment, mild Alzheimer’s disease (AD) dementia, and normal cognition. The longitudinal dataset has elucidated the full cognitive and clinical trajectory of AD from its presymptomatic stage through the onset of dementia. The ADNI data have supported the design of most major trials in the field.
PMID:39136045 | DOI:10.1002/alz.14167
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
The Alzheimer’s Disease Neuroimaging Initiative Clinical Core
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Development of disease-modifying therapies against Alzheimer's disease A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid AmyloidPETNet: Classification of Amyloid Positivity in Brain PET Imaging Using End-to-End Deep Learning Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer's disease Integrating AI in fighting advancing Alzheimer: diagnosis, prevention, treatment, monitoring, mechanisms, and clinical trials Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease Development of a machine learning algorithm to predict the residual cognitive reserve index Neuroimaging to Facilitate Clinical Trials in Huntington's Disease: Current Opinion from the EHDN Imaging Working Group Clinical presentations and diagnostic application of proposed biomarkers in psychiatric-onset prodromal dementia with Lewy bodies Sex-specific clinical and neurobiological correlates of fatigue in older adults Diabetes accelerates Alzheimer's disease progression in the first year post mild cognitive impairment diagnosis MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology Tau pathology mediate the plasma biomarkers and cognitive function in patients with mild cognitive impairment Decentralized clinical trials for medications to reduce the risk of dementia: Consensus report and guidance Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice Novel measures of cognition and function for the AD spectrum in the Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD) project: Psychometric properties, convergent validation, and contrasts with established measures The graded multidimensional geometry of phenotypic variation and progression in neurodegenerative syndromes Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns Primary lateral sclerosis associated with PSEN1 Pro284Leu variant in a Colombian family: Clinical and neuropathological features Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study Low testosterone levels relate to poorer cognitive function in women in an APOE-ε4-dependant manner Low testosterone levels relate to poorer cognitive function in women in an APOE-ε4-dependant manner Temporo-frontoparietal hypoconnectivity as a biomarker for isolated language impairment in mild cognitive impairment: A cross-cohort comparison Dementia Subtypes Defined Through Neuropsychiatric Symptom-Associated Brain Connectivity Patterns TrajVis: a visual clinical decision support system to translate artificial intelligence trajectory models in the precision management of chronic kidney disease TrajVis: a visual clinical decision support system to translate artificial intelligence trajectory models in the precision management of chronic kidney disease New Horizons of Model Informed Drug Development in Rare Diseases Drug Development The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials Hormone therapy is associated with lower Alzheimer's disease tau biomarkers in post-menopausal females -evidence from two independent cohorts Hormone therapy is associated with lower Alzheimer's disease tau biomarkers in post-menopausal females -evidence from two independent cohorts Neonatal dysglycemia: a review of dysglycemia in relation to brain health and neurodevelopmental outcomes Neonatal dysglycemia: a review of dysglycemia in relation to brain health and neurodevelopmental outcomes Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus Using virtual multiteam systems to conduct a multisite randomized clinical trial in the part C early intervention system: Benefits, challenges, and lessons learned Artificial Intelligence in Eye Movements Analysis for Alzheimer's Disease Early Diagnosis Analysis of eligibility criteria in Alzheimer's and related dementias clinical trials From Lab Bench to Hope: Emerging Gene Therapies in Clinical Trials for Alzheimer's Disease From Lab Bench to Hope: Emerging Gene Therapies in Clinical Trials for Alzheimer's Disease An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease Melatonin: A potential nighttime guardian against Alzheimer's The Use of Generative Adversarial Network and Graph Convolution Network for Neuroimaging-Based Diagnostic Classification The Use of Generative Adversarial Network and Graph Convolution Network for Neuroimaging-Based Diagnostic Classification Exploring Neuroimaging Association Scores in adulthood ADHD and middle-age trajectories Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts Psychosis in Alzheimer Disease and Elevations in Disease-Relevant Biomarkers RANO 2.0 criteria: concepts applicable to the neuroradiologist's clinical practice A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce Potential application of artificial intelligence in cancer therapy Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling Integrating programme theory into the development of a core outcome set for technology-assisted counselling interventions in dementia: study protocol of the ProCOS study Psychometric properties of the Spanish version of the Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM) in Chile The role and responsibility of clinical neuroscience in brain-computer interface clinical research Novel Alzheimer's disease subtypes based on functional brain connectivity in human connectome project Artificial intelligence and machine learning's role in sepsis-associated acute kidney injury Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome
Evidence Blueprint
The Alzheimer’s Disease Neuroimaging Initiative Clinical Core
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
The Alzheimer’s Disease Neuroimaging Initiative Clinical Core
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
Development of disease-modifying therapies against Alzheimer's disease Asian Cohort for Alzheimer's Disease (ACAD) pilot study on genetic and non-genetic risk factors for Alzheimer's disease among Asian Americans and Canadians A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome ATN Classification and Clinical Progression of the Amyloid-Negative Group in Alzheimer's Disease Neuroimaging Initiative Participants Polygenic effects on the risk of Alzheimer's disease in the Japanese population Identifying individuals with non-Alzheimer's disease co-pathologies: A precision medicine approach to clinical trials in sporadic Alzheimer's disease Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease An Informatics Platform for the Management of Data for Australian Dementia Network (ADNeT) Initiative Application of Suggestive Biomarkers in Dementia With Lewy Bodies With Masking of Typical Clinical Symptoms by Alzheimer Disease-type Pathology INviting Veterans InTo Enrollment in Alzheimer's Disease Research Centers (INVITE-ADRC): An NIA and VA-sponsored initiative to increase veteran participation in aging and dementia research Ranking and filtering of neuropathology features in the machine learning evaluation of dementia studies Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p-tau217 Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease Meeting report of the fifth annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease Research Artificial intelligence for dementia drug discovery and trials optimization Periodontitis and brain magnetic resonance imaging markers of Alzheimer's disease and cognitive aging AmyloidPETNet: Classification of Amyloid Positivity in Brain PET Imaging Using End-to-End Deep Learning Disentangling Sex-Dependent Effects of APOE on Diverse Trajectories of Cognitive Decline in Alzheimer's Disease Psychotic symptoms are associated with elevated tau PET signal in the amygdala independent of Alzheimer's disease clinical severity and amyloid burden Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology Down Syndrome Biobank Consortium: A perspective Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females Genome-wide association studies identify novel loci in rapidly progressive Alzheimer's disease Clinical value of Alzheimer's disease biomarker testing Clinical value of Alzheimer's disease biomarker testing Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer's disease Integrating AI in fighting advancing Alzheimer: diagnosis, prevention, treatment, monitoring, mechanisms, and clinical trials A multimodal deep learning approach for the prediction of cognitive decline and its effectiveness in clinical trials for Alzheimer's disease Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration Patterns of Glucose Metabolism in [ 18 F]FDG PET Indicate Regional Variability and Neurodegeneration in the Progression of Alzheimer's Dementia Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease Management of treatment resistance-Treatment-resistant schizophrenia Development of a machine learning algorithm to predict the residual cognitive reserve index Effectiveness of multimodal participant recruitment in SPARK, a large, online longitudinal research study of autism INFLAMMATION's cognitive impact revealed by a novel "Line of Identity" approach A novel neuroimaging signature for ADRD risk stratification in the community The SNP rs6859 in NECTIN2 gene is associated with underlying heterogeneous trajectories of cognitive changes in older adults Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity Neuroimaging to Facilitate Clinical Trials in Huntington's Disease: Current Opinion from the EHDN Imaging Working Group Advances in nanoprobes for molecular MRI of Alzheimer's disease Clinical presentations and diagnostic application of proposed biomarkers in psychiatric-onset prodromal dementia with Lewy bodies Sex-specific clinical and neurobiological correlates of fatigue in older adults Statin use moderates APOE's and CRP's associations with dementia and is associated with lesser dementia severity in ε4 carriers Diabetes accelerates Alzheimer's disease progression in the first year post mild cognitive impairment diagnosis MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population Different cohort, disparate results: Selection bias is a key factor in autopsy cohorts Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology Tau pathology mediate the plasma biomarkers and cognitive function in patients with mild cognitive impairment Amyloid Pathology Modulates the Associations of Neuropsychiatric Symptoms with Cognitive Impairments and Neurodegeneration in Non-Demented Elderly Updated safety results from phase 3 lecanemab study in early Alzheimer's disease Beyond Hypertension: Examining Variable Blood Pressure's Role in Cognition and Brain Structure Increasing sensitivity of clinical proverb tests for diagnosis of dementia Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's Disease Neuroprotection Research Initiative (ADNRI) Decentralized clinical trials for medications to reduce the risk of dementia: Consensus report and guidance Reply to Kljajevic's "Increasing sensitivity of clinical proverb tests for diagnosis of dementia" Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice